How health technology reassessment can support disinvestment in China’s national drug reimbursement list

A requirement to assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment, say Lizheng Shi and colleagues

Detalles Bibliográficos
Autores principales: Shi, Lizheng, Wu, Jiuhong, Meng, Qingyue, Li, Dakui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2023
Materias:
Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266436/
https://www.ncbi.nlm.nih.gov/pubmed/37321624
http://dx.doi.org/10.1136/bmj-2021-068917
_version_ 1785058740513275904
author Shi, Lizheng
Wu, Jiuhong
Meng, Qingyue
Li, Dakui
author_facet Shi, Lizheng
Wu, Jiuhong
Meng, Qingyue
Li, Dakui
author_sort Shi, Lizheng
collection PubMed
description A requirement to assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment, say Lizheng Shi and colleagues
format Online
Article
Text
id pubmed-10266436
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-102664362023-06-15 How health technology reassessment can support disinvestment in China’s national drug reimbursement list Shi, Lizheng Wu, Jiuhong Meng, Qingyue Li, Dakui BMJ Analysis A requirement to assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment, say Lizheng Shi and colleagues BMJ Publishing Group Ltd. 2023-06-15 /pmc/articles/PMC10266436/ /pubmed/37321624 http://dx.doi.org/10.1136/bmj-2021-068917 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Analysis
Shi, Lizheng
Wu, Jiuhong
Meng, Qingyue
Li, Dakui
How health technology reassessment can support disinvestment in China’s national drug reimbursement list
title How health technology reassessment can support disinvestment in China’s national drug reimbursement list
title_full How health technology reassessment can support disinvestment in China’s national drug reimbursement list
title_fullStr How health technology reassessment can support disinvestment in China’s national drug reimbursement list
title_full_unstemmed How health technology reassessment can support disinvestment in China’s national drug reimbursement list
title_short How health technology reassessment can support disinvestment in China’s national drug reimbursement list
title_sort how health technology reassessment can support disinvestment in china’s national drug reimbursement list
topic Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266436/
https://www.ncbi.nlm.nih.gov/pubmed/37321624
http://dx.doi.org/10.1136/bmj-2021-068917
work_keys_str_mv AT shilizheng howhealthtechnologyreassessmentcansupportdisinvestmentinchinasnationaldrugreimbursementlist
AT wujiuhong howhealthtechnologyreassessmentcansupportdisinvestmentinchinasnationaldrugreimbursementlist
AT mengqingyue howhealthtechnologyreassessmentcansupportdisinvestmentinchinasnationaldrugreimbursementlist
AT lidakui howhealthtechnologyreassessmentcansupportdisinvestmentinchinasnationaldrugreimbursementlist

Ejemplares similares